Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia, Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/2/2017 |
| Start Date: | July 2002 |
| End Date: | September 2004 |
Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia
The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.),
along with another drug called an aminoglycoside (a different type of antibiotic) is
effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa,
Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult
to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory
support. The study hopes to show that by increasing the amount of meropenem administered and
increasing the duration of infusion (release of the drug into the bloodstream), levels of the
drug will stay at target levels in the bloodstream and decrease the ability of difficult to
treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem)
or other antibiotics.
along with another drug called an aminoglycoside (a different type of antibiotic) is
effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa,
Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult
to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory
support. The study hopes to show that by increasing the amount of meropenem administered and
increasing the duration of infusion (release of the drug into the bloodstream), levels of the
drug will stay at target levels in the bloodstream and decrease the ability of difficult to
treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem)
or other antibiotics.
Inclusion Criteria:
- Onset or exacerbation of pneumonia at least 72 hours after admission to an acute care
facility or onset of pneumonia in a nursing home or rehabilitation facility with
subsequent transfer to an acute care facility
- Diagnosis of hospital-acquired pneumonia requiring mechanical ventilatory support
- Patient or Patient's legal guardian must sign written informed consent for study
participation, pretreatment, and Day 7 bronchoscopy
Exclusion Criteria:
- Patients with hospital-acquired pneumonia caused by pathogens resistant to MERREM
- Patients with allergies to cephalosporins, penicillins and carbapenems
- Patients taking anticonvulsant therapy for a known seizure disorder
- Patients with lung cancer
- Patients with cystic fibrosis, acquired immune deficiency syndrome (AIDS),
neutropenia, active tuberculosis, or patients taking immunosuppressive therapy in
preparation for or following an organ transplant.
- Patients who are pregnant or breast feeding
- Patients who are unlikely to survive
- Patients with certain infections in another area requiring treatment with additional
antibiotics
- Patients with other underlying conditions that would make it difficult to interpret
response to study drug.
- Patients who have been part of another clinical study 30 days before entry into this
study.
- Patients with hypotension (systolic BP < 85mmHg) or acidosis (arterial pH <7.25 or
serum bicarbonate <15 mg/dl) despite attempts at fluid resuscitation
- Patients with profound hypoxia
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials